Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2012

Is Fixed-combination Prostaglandin Analog/βblocker Therapy Safe and More Effective than βblocker Monotherapy in the Prevention of Disease
Progression in Adults with Open-angle Glaucoma?
My-Hang Pham
Philadelphia College of Osteopathic Medicine, MyHangPh@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Chemicals and Drugs Commons, and the Eye Diseases Commons
Recommended Citation
Pham, My-Hang, "Is Fixed-combination Prostaglandin Analog/β-blocker Therapy Safe and More Effective than β-blocker
Monotherapy in the Prevention of Disease Progression in Adults with Open-angle Glaucoma?" (2012). PCOM Physician Assistant
Studies Student Scholarship. Paper 77.

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is fixed-combination prostaglandin analog/β-blocker therapy safe and more effective than βblocker monotherapy in the prevention of disease progression in adults with open-angle
glaucoma?

My-Hang Pham, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirement for
The Degree of Master of Science
In
Health Sciences – Physician Assistant

Department of Physician Assistant
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 16, 2011

ABSTRACT
Objective – The objective of this selective EBM review is to determine whether fixedcombination prostaglandin analog/β-blocker therapy is safe and more effective than β-blocker
monotherapy in the prevention of disease progression in adults with open-angle glaucoma.
Study Design – Review of three English language randomized controlled trials published in
2008 and 2010.
Data sources – 3 randomized, controlled, double-blind trials comparing fixed-combination
prostaglandin analog/β-blocker therapy to β-blocker monotherapy were found using Pubmed,
Medline, and Cochrane databases.
Outcome Measured – Disease progression/regression was assessed by post-baseline
measurement of IOP during three follow-up visits throughout the trials. The safety profile of
each therapy was assessed by monitoring the number of adverse events reported by the
participants or observed by the researchers.
Results – All three studies demonstrated a significantly greater IOP reduction in participants
treated with fixed combination prostaglandin analog/β-blocker therapy. There was a
significantly higher incidence of adverse events in the fixed combination group compared to the
β-blocker monotherapy group; however, the fixed combination therapy was determined to be
well-tolerated and superior over β-blocker monotherapy in the prevention of disease progression
of open-angle glaucoma.
Conclusions – Fixed combination prostaglandin analog/β-blocker therapy is safe and more
effective than β-blocker monotherapy in the prevention of disease progression in adults with
open-angle glaucoma. The simple dosing schedule increases patient adherence compared to the
more complex multi-drug regimen of the individual active components.
Key Words – “open-angle glaucoma”, “combination therapy”, “prostaglandin analog”, “βblocker”
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INTRODUCTION
Open-angle glaucoma (OAG) is a progressive disease characterized by insidious optic
nerve damage that is commonly attributed to chronic intraocular pressure (IOP) elevation.1, 2
In this type of glaucoma, IOP elevation is due to impaired drainage of aqueous fluid through the
trabecular meshwork to the anterior chamber. The exact mechanism of optic nerve damage by
increased IOP is not yet understood.1 However, chronically elevated IOP results in optic nerve
atrophy and enlargement of cup-to-disc ratio, consequently leading to visual field impairment
progressing to irreversible vision loss.1,2
Early detection and prompt treatment of OAG is important within the practice of
physician assistants since glaucoma is one of the leading causes of preventable blindness in the
United States.1 Glaucoma affects more than two million Americans, accounting for an estimate
of more than seven million office visits annually and $1.5 billion in direct healthcare cost.3 The
prevalence of OAG is highest in diabetic patients and those with affected first-degree relatives.2
Chronic IOP elevation in OAG is often asymptomatic until severe optic nerve damage has
already occurred and permanent visual impairment has ensued.1,2 Therefore routine screening
and early treatment of glaucoma are essential to halt the progression of the disease and to prevent
irreversible visual loss.
The treatment of OAG and blindness prevention can be achieved through pharmacologic
agents aimed at reducing the IOP by decreasing aqueous fluid production or increasing aqueous
fluid outflow. Topical agents to suppress aqueous production include β-adrenergic blocking
agents, alpha2-adrenergic agonists and carbonic anhydrase inhibitors.1,2 Agents that facilitate
aqueous outflow include prostaglandin analogs and parasympathomimetic agents. Laser
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trabeculoplasty and glaucoma drainage surgery (trabeculectomy) are effective treatments for
patients with inadequate response to the less invasive medical treatments.2
Most patients with OAG respond well to medical treatments. Nonetheless, there are still
a large number of patients who require more than one topical agent for adequate IOP control.
Prostaglandin analogs and β-blockers are often first-line agents and may be used concurrently to
maximize IOP reduction due to their different mechanisms of action.2 However, the complexity
of multi-drug regimen due to their different dosing schedule has made it a challenge to achieve
satisfactory patient compliance.4,5 Therefore, many formulations of fixed-combination
prostaglandin analog/β-blocker have been developed to enhance patient adherence to effectively
treat and prevent the progression of glaucoma.
OBJECTIVE
The objective of this selective EBM review is to determine whether fixed-combination
prostaglandin analog/β-blocker therapy is safe and more effective than β-blocker monotherapy in
the prevention of disease progression in adults with open-angle glaucoma.
METHODS
All three studies included in this selective EBM review were randomized, double-blind,
controlled trials. The studied population included patients 18 years of age or older with openangle glaucoma or ocular hypertension. The intervention used in the randomized controlled
trials was fixed-combination prostaglandin analog/β-blocker therapy. The treatment group was
compared to a comparison group in which patients only received β-blocker monotherapy.
The article search was performed by the author of this selective review using PubMed,
MEDLINE, and Cochrane databases with keywords “open-angle glaucoma”, “combination
therapy”, “prostaglandin analog”, and “β-blocker”. All three articles were published in English
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in peer-reviewed journals. Inclusion criteria for the search were randomized controlled trials and
publication date between 1996 to present. Exclusion criteria included systematic reviews,
studies published prior to 1996, animal trials, and patients under 18 years of age. Table 1
outlined the demographics and characteristics of the included studies.
Table 1. Demographics and characteristics of included studies
Study
Higginbot
ham et al.,
2010

Type
RCT

# Pts
394

Age
> 18

Inclusion Criteria
- primary OAG or
ocular HTN
- Were receiving a βblocker for > 4
weeks before
screening.
- mean IOP between
26-36 mmHg
- best-corrected visual
acuity of 20/200 or
better

Exclusion criteria
- Angle-closure glaucoma
- hx of ocular procedure,
inflammation w/i 3
months or infection w/i 3
wks before screening
- use a systemic med
known to affect IOP
- contraindicated to βblocker
- hypersensitivity to
benzalkonium chloride
- abnormal ocular
conditions or
uncontrolled systemic ds
- women of childbearing
potential w/o
contraceptive methods or
were pregnant/ nursing.

W/D
56

Interventions
Fixedcombination
latanoprost/ti
molol
maleate vs.
individual
components

Varma et
al., 2010

RCT

854

> 18

- primary OAG or
ocular HTN
- IOP ≥ 30 mmHg w/o
ocular hypertensive
meds or ≥ 25 mmHg
with prior therapy

- Not specified

Not
specified

fixed
combination
latanoprost/ti
molol vs.
individual
components

Brandt et
al., 2008

RCT

1061

> 18

- ocular HTN, OAG,
or angle-closure
glaucoma, and who
required B/L ocular
hypotensive tx
- best corrected visual
acuity of 20/200 or
better O.U.
- IOP > 24 mmHg

- uncontrolled systemic ds,
significant ocular
irritation, or active ocular
ds
- contraindications to tx w/
study meds or their
components
- conditions that precluded
accurate IOP readings
- surgery w/i the past 3
months
- Concomitant ocular
meds
- Pregnant women or
women of childbearing
age w/o adequate
contraceptive methods

74

fixed
combination
Bimatoprost/t
imolol vs.
individual
components
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OUTCOMES MEASURED
The outcomes measured in all three RCTs include disease progression/regression and
safety, which are both patient oriented evidence that mattered to the patients (POEMs). Since
OAG is an asymptomatic and insidious condition, disease progression was defined as an increase
in IOP and disease regression as a reduction in IOP. Lowering IOP halts optic nerve damage and
prevents the progression of the disease to complete irreversible blindness. Several studies have
proposed that long-term large diurnal IOP fluctuation may be associated with disease
progression. Therefore Varna et al. also studied the effectiveness of fixed combination therapy
on the reduction of diurnal IOP fluctuation.6 Higginbotham et al. and Brandt et al. investigated
the safety profile of the intervention by assessing the number overall reported adverse event and
ocular-related adverse events.4,5
Brandt et al. and Higginbotham et al. scheduled follow-up IOP measurements at weeks 2,
6, and 12;4,5 Varna et al. scheduled follow-up IOP measurements at weeks 2, 13, and 26.6 The
IOP for each participant in all three studies was measured at three different times during each
follow-up visit. The diurnal IOP was the average of the three IOP measurements during each
visit; and diurnal IOP fluctuation was the difference between the highest and lowest IOP of the
three measurements taken at each visit.4,5,6 Varna et al. also converted the diurnal IOP
fluctuation into dichotomous data as high (> 6 mmHg) and low (< 6 mmHg).6
The safety profile of the intervention and comparison group was analyzed by monitoring
the number of adverse events reported by the participants or observed by the researchers. The
severity of the adverse event and whether it was treatment-related were also assessed by the
researchers. Treatment-related adverse events were defined as those with onset or worsening
after the initiation of the therapy.4,5
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RESULTS
The study performed by Brandt et al. demonstrated statistically significant (p < 0.001)
mean decreases from baseline IOP by the end of the trial of 8.1 + 3.3 mmHg and 6.4 + 3.5
mmHg for the fixed combination therapy and β-blocker monotherapy, respectively. The efficacy
of the treatment was measured as a mean diurnal reduction greater than 20% from baseline IOP
and IOP of less than 18 mmHg.4 The percentage of participants achieving > 20% reduction from
baseline IOP were 81.8% for the combination group and 49.8% for the β-blocker group; and the
percentage of those with IOP < 18 mmHg were 39.2% and 12.2%, respectively (Table 2).4 The
number needed to treat based on the data on IOP reduction is 4.
Table 2. The efficacy and safety of each treatment group reported by Brandt et al.
Efficacy
Safety
> 20% reduction*
< 18 mmHg*
# treatment-related AEs*
81.8 %
(436/533)

39.2%
(209/533)

41.5 %
(221/533)

49.8 %
β-blocker
(131/263)
monotherapy
Number needed to treat: 4
* Between-group p value: p < 0.001

12.2 %
(32/263)

24.7 %
(65/263)

Fixed combination

Higginbotham et al. reported statistically significant (p < 0.001) mean IOP differences
(fixed combination – monotherapy) between the fixed combination group and the β-blocker
group ranging from -3.79 mmHg to -2.14 mmHg. The baseline diurnal IOP values were similar
between the two treatment groups; however, the postbaseline diurnal IOP values at weeks 6 and
12 were significantly lower in the fixed combination group compared to those of the β-blocker
group (Table 3).5 Higginbotham et al. also reported a significantly higher percentage of
participants in the fixed-combination group achieving a mean diurnal IOP of < 18 mmHg by the
conclusion of the study, p <0.01.5
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Table 3. Mean diurnal IOP reported in Higginbotham et al.
Mean diurnal IOP (SD), mmHg
Combination therapy
β -blocker monotherapy
28.0 (2.2)
28.1 (2.3)
Baseline
a
17.9 (3.3)
20.9 (3.7)
Week 6
b
17.8 (3.5)
20.9 (3.5)
Week 12
a
Mean difference (95% CI): - 2.83 mmHg (-3.54 to -2.11 mmHg); p < 0.001
b
Mean difference (95% CI): -3.02 mmHg (-3.79 to -2.24 mmHg); p < 0.001

Varna et al. reported a statistically significant (p < 0.01) lower mean diurnal IOP in
patients treated with the fixed combination compared to those treated with β-blocker
monotherapy, 19.4 mmHg and 22.4 mmHg, respectively. The differences from baseline to week
26 were -2.9 mmHg for the fixed combination group and -0.7 mmHg for the β-blocker group; p
< 0.01.6 The diurnal IOP fluctuation of participants in the fixed combination group was
significantly lower in week 26 than was at baseline; p = 0.002; while there was a statistically
insignificant increase in the diurnal IOP fluctuation of participants treated with β-blocker
monotherapy; p = 0.097.6 The between-treatment difference was statistically significant (p <
0.01) (Table 4).6 The dichotomized data of the diurnal IOP fluctuation also demonstrated
significantly fewer patients with “high” ( > 6 mmHg) IOP fluctuation in the fixed combination
group than in the monotherapy group; p = 0.003. There was a reduction in the percentage of
participants with “high” IOP fluctuation in the fixed combination group (13.3% at baseline vs.
6.9% at week 26); whereas there was an insignificant increase in patients with “high” IOP
fluctuation in the β-blocker monotherapy group (13.2% at baseline vs 14.9% at week 26; p =
0.08) (Table 5).6 The number needed to treat based on the dichotomized diurnal IP fluctuation is
14.
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Table 4. Mean diurnal IOP fluctuation at baseline and week 26 reported by Varna et al.
Mean diurnal IOP fluctuation (SD), mmHg
Fixed combination
β -blocker monotherapy
3.7 (2.5)
3.4 (2.3)
Baseline
3.0 (2.1)
3.7 (3.2)
Week 26
b
a
-0.68 (0.22)
0.36 (0.22) c
∆ (baseline - wk 26)
a
between-treatment p value: p < 0.001
b
within-treatment p value: p = 0.002
c
within-treatment p value: p = 0.097
Table 5. The number of participants with high (> 6 mmHg) and low (< 6 mmHg) mean
diurnal IOP fluctuation as reported in Varna et al.
Mean diurnal IOP fluctuation
Fixed combination
β -blocker monotherapy
a
Baseline
High ( > 6 mmHg)
37 (13.3%)
28 (9.7%)
Low ( < 6 mmHg)
241 (86.7%)
261 (90.3%)
b
Week 26
High ( > 6 mmHg)
19 (6.9%)
41 (14.4%)
Low ( < 6 mmHg)
256 (93.1%)
243 (85.6%)
Number needed to treat: 14
a
between-treatment p value: p = 1.078
b
between-treatment p value: p = 0.003
The percentages of participants reporting an adverse event in Brandt et al. were 41%
(221/533) for the fixed combination group and 24.7% (65/263) for the β-blocker group, p <
0.001. The percentage of participants in Higginbotham et al. reporting an adverse event were
29.5% (49/134) for the fixed combination group and 23.7% (31/131) for the β-blocker group,
with total numbers of reported adverse events of 58 and 48, respectively. However, the
statistical significance of this difference between the two treatment groups was not included in
the data. The number needed to harm was 6 for the Brandt et al. study and 17 for the
Higginbotham et al. study (Table 6).
Table 6. Treatment-related adverse events reported in Brandt et al. and Higginbotham et al.
ERR
CER
RR
RRI
ARI
NNH
0.415
0.247
1.68
0.68
0.168
6
Brandt et al.
0.295
0.237
1.24
0.245
0.058
17
Higginbotham et al.
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DISCUSSION
All three included studies demonstrated that fixed combination prostaglandin analog/βblocker is safe and significantly more effective than β-blocker monotherapy in the prevention of
disease progression in patients with open-angle glaucoma.4,5,6 The two active ingredients of the
fixed combination provided additive IOP reduction by affecting the aqueous level in two
different mechanisms: decreased aqueous humor production by β-blocker and increased aqueous
outflow by prostaglandin analog.1, 2 There was a significantly higher number of participants
maintaining a IOP of < 18 mmHg, which is the visual field progression threshold defined by the
Advanced Glaucoma Intervention Study.5 Lowering IOP reduces optic nerve damage and
therefore halts the progression of the disease to complete blindness. The Collaborative Initial
Glaucoma Treatment Study had suggested that a decrease in IOP of 35% or more could prevent
the progression of optic nerve damage over a 5-year period.5
Brandt el al. and Higginbotham et al. reported greater numbers of treatment-related
adverse events in participants treated with fixed combination therapy compared to those treated
with β-blocker monotherapy. Neither study reported serious treatment-related adverse event that
resulted in discontinuation of the study. The most common adverse event was conjunctival
hyperemia. Other reported adverse events were burning sensation in eye, eye pruritus and
dryness, growth of eyelashes, foreign body sensation,…4,5 Brandt et al. suggested that the lower
incidence of conjunctival hyperemia in patients treated with β-blocker monotherapy may be
class-related. The β2-antagonistic activity of β-blockers decreases nitric oxide production,
consequently leading to less hyperemia.4 Additionally, the unopposed alpha1-agonistic effects of
endogenous catecholamines due to β-blockade may also contribute to decreased hyperemia in the
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β-blocker monotherapy group.4 Overall, the fixed combination of prostaglandin analog/βblocker is well-tolerated and safe for the prevention disease progression of open-angle glaucoma.
All three studies included in this review are randomized controlled trials with an adequate
sample size. However, one limitation of the study performed by Varna et al. is limited is that it
was a posthoc analysis.6 Additionally, although fixed-combinations of prostaglandin analog/βblocker provide superior IOP reduction than β-blocker monotherapy, these formulations are not
yet available in the United States. Ganfort (bimatoprost 0.03% and timolol maleate 0.5%) is
only available in certain countries, while Xalacom (latanoprost 0.005% and timolol maleate
0.5%) and DuoTrav (travoprost 0.004% and timolol 0.5%) are only available in Canada.7
CONCLUSION
Overall, fixed combination prostaglandin analog/β-blocker can be recommended for
additional IOP reduction to help prevent disease progression in patients with open-angle
glaucoma requiring more than one topical treatment. The fixed combination therapy was found
to be safe and more effective than β-blocker monotherapy. Additionally, it is also well-tolerated;
and its convenient simple dosing schedule increases patient adherence, maximizing long-term
IOP reduction and therefore preventing the progression of the disease. Future study is warranted
to determine whether the fixed combination therapy is superior to multi-drug regimens of its
individual active components in prevention of OAG disease progression.
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